Cinctive Capital Management LP Boosts Stock Position in Repligen Co. (NASDAQ:RGEN)

Cinctive Capital Management LP increased its holdings in shares of Repligen Co. (NASDAQ:RGEN) by 717.1% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 61,398 shares of the biotechnology company’s stock after buying an additional 53,884 shares during the period. Cinctive Capital Management LP owned about 0.11% of Repligen worth $8,838,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also recently added to or reduced their stakes in the company. Signaturefd LLC grew its position in shares of Repligen by 172.2% in the fourth quarter. Signaturefd LLC now owns 196 shares of the biotechnology company’s stock valued at $28,000 after purchasing an additional 124 shares during the period. Sava Infond d.o.o. acquired a new position in Repligen during the fourth quarter worth about $29,000. Resources Management Corp CT ADV purchased a new stake in Repligen during the 3rd quarter valued at about $37,000. Quarry LP raised its holdings in Repligen by 796.7% in the 3rd quarter. Quarry LP now owns 269 shares of the biotechnology company’s stock valued at $40,000 after acquiring an additional 239 shares during the last quarter. Finally, UMB Bank n.a. lifted its stake in Repligen by 49.1% in the 4th quarter. UMB Bank n.a. now owns 334 shares of the biotechnology company’s stock worth $48,000 after purchasing an additional 110 shares in the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

Insider Transactions at Repligen

In other Repligen news, Director Margaret Pax bought 250 shares of the firm’s stock in a transaction dated Monday, March 17th. The stock was acquired at an average price of $150.69 per share, for a total transaction of $37,672.50. Following the completion of the purchase, the director now owns 1,043 shares of the company’s stock, valued at approximately $157,169.67. This represents a 31.53 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 1.20% of the company’s stock.

Repligen Stock Performance

Shares of RGEN opened at $128.50 on Wednesday. The company has a market capitalization of $7.22 billion, a price-to-earnings ratio of -251.96, a price-to-earnings-growth ratio of 4.54 and a beta of 0.95. The company has a quick ratio of 8.76, a current ratio of 10.44 and a debt-to-equity ratio of 0.26. Repligen Co. has a 52-week low of $113.50 and a 52-week high of $182.52. The stock has a 50 day moving average price of $152.75 and a 200 day moving average price of $148.00.

Repligen (NASDAQ:RGEN) last released its quarterly earnings data on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.41 by $0.03. Repligen had a negative net margin of 4.64% and a positive return on equity of 4.21%. The company had revenue of $167.55 million during the quarter, compared to the consensus estimate of $167.58 million. Research analysts predict that Repligen Co. will post 1.72 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on RGEN shares. Canaccord Genuity Group upped their price target on Repligen from $165.00 to $170.00 and gave the company a “hold” rating in a research report on Friday, February 21st. HC Wainwright reaffirmed a “buy” rating and set a $180.00 price objective on shares of Repligen in a research report on Friday, February 21st. StockNews.com cut Repligen from a “hold” rating to a “sell” rating in a research note on Friday, February 21st. Canaccord Genuity Group assumed coverage on Repligen in a research note on Tuesday, December 17th. They issued a “hold” rating and a $165.00 price objective for the company. Finally, TD Cowen assumed coverage on Repligen in a research note on Monday, February 10th. They set a “buy” rating and a $200.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and eight have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $178.64.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.